Kuva's $4.00 Tender Offer for Lisata Therapeutics (LSTA), Plus a CVR Worth Up to $3.00 — and Why It Trades Below Cash

Lisata Therapeutics, Inc. (NASDAQ: LSTA), a clinical-stage cancer-drug developer, is the target of a takeover launched June 10, 2026 by Kuva Acquisition Corp., a wholly-owned subsidiary of privately held Kuva Labs, Inc. The deal pays $4.00 per share in cash plus one contingent value right worth up to $3.00. On paper that is up to $7.00 a share. In reality, with LSTA trading near $3.47 — below the cash component by itself — the market is telling you this is anything but a sure thing. This piece walks through the cash-versus-CVR math, the financing problem that is the heart of the story, the spread, and what an investor actually has to weigh before July 10.

The Offer

Kuva is offering two pieces of consideration for each Lisata share. The first is $4.00 per share in cash at closing. The second is one CVR — a contractual IOU that pays cash later only if certain milestones are hit. A tender offer is simply an open invitation from a buyer to all shareholders to sell their shares directly at a set price by a set deadline.

The CVR here carries two possible payments totaling up to $3.00:

• $1.25 if the "First Milestone" is achieved — enrollment in Lisata's Phase 2a glioblastoma study of certepetide (LSTA1) added to standard-of-care temozolomide. This payment is due on the later of December 15, 2026 or 45 days after the milestone is met.
• $1.75 if the "Second Milestone" is achieved — the filing or acceptance of a New Drug Application (NDA), or an equivalent regulatory submission anywhere in the world, for certepetide. This is payable 45 days after achievement, any time before the CVR expires on the seventh anniversary of closing.

The CVR is non-tradeable: you cannot sell it, so once the deal closes you hold a stub that pays $0.00, $1.25, or $3.00 — nothing in between unless only one milestone hits — over a window stretching up to seven years. There is no interest, and Kuva is only obligated to use "commercially reasonable efforts" on the NDA milestone, which holders cannot legally force.

Lisata's board of directors unanimously recommends that stockholders tender. After the offer, Kuva will complete a back-end merger under Section 251(h) of Delaware law — a provision that lets a buyer who has acquired enough shares in the tender offer absorb the rest without a shareholder vote, cashing out non-tendering holders at the identical $4.00-plus-CVR price. So this is a full buyout, not a partial offer, and doing nothing still gets you cashed out at the same terms.

The Financing Problem Is the Whole Story

Normally with a clean cash deal you focus on the spread. Here you have to start with whether the buyer can pay at all.

Kuva's own offer documents say it plainly: as of the commencement of the offer, Kuva and its acquisition vehicle do not have committed financing to fund the offer price, and "there can be no assurance that such financing will be obtained." Kuva intends to raise the money through some combination of debt and equity from third parties, none of which is locked down. The deal carries no financing condition — which sounds protective, but it cuts the other way: it means a failure to fund is a breach, not a clean exit for Kuva. That is cold comfort if the buyer simply has no cash; you cannot squeeze money from a shell that does not have it.

The track record so far is not reassuring. The transaction was first signed in March 2026 at richer terms. Kuva then slipped the tender-offer launch repeatedly — at one point telling Lisata at the last minute that it would not commence on schedule because it was still "negotiating with its potential financing sources." The parties pushed the outside date out to July 17, 2026, with an option to extend to August 17 only if Kuva pays Lisata a non-refundable $1.5 million fee. Kuva even missed a $250,000 operating payment to Lisata and had to agree to a staged catch-up, with Lisata retaining the right to terminate if Kuva misses again.

That is the context for why the cash portion was cut. When this deal was first announced in March it was $5.00 per share in cash plus a single $1.00 CVR. The current terms drop the guaranteed cash by a dollar to $4.00 and enlarge the CVR to up to $3.00 — in other words, a dollar of certain cash was swapped for two dollars of speculative, milestone-dependent, illiquid contingent value. Lisata's filings do not spell out the rationale, but the timing lines up exactly with Kuva's financing struggles: a buyer that cannot fund $5.00 re-trades the deal lower and shifts risk onto sellers. You can read the buyer's own funding disclosures in the Schedule TO filed with the SEC.

The Spread: Below Cash for a Reason

With LSTA near $3.47 against a $4.00 cash component, the stock sits roughly 13% under the cash you would receive at closing ((4.00 − 3.465) / 4.00 = 13.4%). Put the other way, if the deal closed tomorrow at just the cash price, a buyer at today's level would make about 15% ((4.00 − 3.465) / 3.465 = 15.4%) — before counting a penny of CVR.

That is a wide gap for a deal that has already commenced, and it exists precisely because the market doubts the close. Stocks in live cash tender offers usually trade just under the cash price, reflecting a small return for the few weeks of remaining risk. LSTA trading well below cash is the market assigning a meaningful probability that Kuva never funds and the agreement terminates, sending the shares back toward pre-deal levels (the 52-week range is $1.86–$5.04).

If you believe the deal closes, the reward is asymmetric: about 15% on the cash alone, and theoretically up to roughly 102% if both CVR milestones eventually pay ((7.00 − 3.465) / 3.465). But that top number is fantasy math — it requires an NDA that does not exist today. The honest framing is a binary: collect the cash if Kuva funds, or take a sharp loss if it walks.

How Much Is the CVR Really Worth?

Treat the two milestones very differently.

The $1.25 glioblastoma milestone is the achievable one. It is tied to enrolling patients in a small (~30-patient) Phase 2a study — not to the trial succeeding. The trigger is reaching enrollment (or even the sponsor terminating the trial), and enrollment is expected to wrap by the end of 2026. That is a low, near-term bar, so if the deal closes at all, this $1.25 is reasonably likely to pay.

The $1.75 NDA milestone is a long shot. Certepetide is an RGD peptide designed to help chemotherapy penetrate tumors; it holds FDA Fast Track status, and Lisata's Greater China rights recently reverted from a partner, leaving the asset globally unencumbered. But the lead data, from the ASCEND Phase 2b study in pancreatic cancer, was mixed — encouraging progression-free-survival signals but a roughly flat overall-survival readout. No NDA exists, and getting to one would require a successful pivotal trial first. Over a seven-year window it is possible, but you should value it as a cheap lottery ticket, not as $1.75 of expected value.

A Quick Word on Taxes

Because Lisata is a U.S. Delaware company and this is a cash deal, tendering (or being cashed out in the back-end merger) is a taxable sale for U.S. holders — generally a capital gain or loss on the $4.00 cash versus your cost basis, long-term if you have held more than a year. The CVR is the messy part: non-tradeable CVRs are typically taxed when milestone payments actually arrive, and a portion of those later payments can be recharacterized as ordinary interest income. Confirm the specifics in the offer's tax section and with your own advisor before tendering.

Timeline

What an Investor Should Weigh

This is not a typical merger-arb "clip the spread" setup; it is a financing bet dressed up as a buyout. The reason LSTA trades below the $4.00 cash is that the buyer has openly disclosed it does not yet have the money, has already missed deadlines and a payment, and re-cut the deal lower once. Until Kuva announces committed financing, every other detail — the board's blessing, the no-financing-condition language, the CVR upside — is secondary.

Key terms to keep in view:

• Minimum tender condition: Kuva must receive enough shares (together with rollover shares from insiders) to complete the Section 251(h) merger. The unanimous board recommendation helps participation, but the offer can be extended if the threshold is not met.
• Withdrawal rights: any shares you tender can be pulled back at any time until the offer expires, so tendering is not an irrevocable commitment before July 10.
• Termination fee: the break fee is small relative to the roughly $36 million cash deal, which limits the financial penalty on a buyer that chooses to walk.
• Litigation noise: plaintiff firms have issued the customary "investigation" notices questioning whether the board secured a fair price; some of those notices still describe the old CVR structure and have not produced filed complaints in the public record.

The bull case is straightforward: a board-endorsed deal at $4.00 cash, plus a free option on $1.25–$3.00 of CVR, bought today below the cash price. The bear case is equally clear: an unfunded private acquirer that has repeatedly failed to launch on time could terminate, and a stock that fell from above $5.00 to $3.47 can keep falling toward $1.86. The deciding variable is one headline — whether and when Kuva secures committed financing. Watch the SEC filings closely; you can follow them on Lisata's EDGAR page, and read the company's own framing in its commencement announcement. For background on how these deals work, the SEC's primer on tender offers is a useful reference.

This analysis is for informational purposes only and is not investment advice. Read the complete filings and consult your own advisors before making any decisions.